DASL-HiCaP

• Research type

  Research Study

• Full title

  DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

• IRAS ID

  285961

• Contact name

  Simon Hughes

• Contact email

  simon.1.hughes@kcl.ac.uk

• Sponsor organisation

  Cancer Trials Ireland

• Eudract number

  2019-004818-34

• Clinicaltrials.gov Identifier

  NCT04136353

• Duration of Study in the UK

  8 years, 4 months, 1 days

• Research summary

  A clinical research study to investigate whether the addition of a new medication (darolutamide) to standard treatment is better for improving the outcomes for men with localised prostate cancer compared to standard treatment.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  20/LO/1283

• Date of REC Opinion

  21 Jan 2021

• REC opinion

  Further Information Favourable Opinion